The advantage of HSP vaccine, compared to other tumor vaccines, is its highly specificity of the interaction between HSPPC-96 and APCs, and therefore, better eliciting robust CD4 + and CD8 + T-cell immune responses. The gene discussed is CD8A; the disease is neoplasm.